Across 7 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of The Cooper Companies news is Neutral (-2)
on a scale from −100 to +100.
That is down 5 points from the previous 30 days (+3).
📈 Cooper generated $678M free cash flow, up from $189M two years prior.
📉 Stock fell 13.3% despite 5.6% yield while underperforming the S&P 500.
Somewhat Bearish -25
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
AI-generated analysis
Key insights
📈 Cooper Companies generated $678 million in free cash flow over the twelve months to July 31, 2026, representing a significant increase from $189 million two years prior.
📉 The stock price has declined 13.3% over the past year despite producing a 5.6% free cash flow yield, underperforming the S&P 500 which returned 12.2%.
📉 CooperVision's fiscal Q3 2026 revenue was flat year-over-year at $717 million, prompting management to cut its organic growth forecast for fiscal 2026 to 1.5%.
⚖️ Operating margins fell to 12.8% from 18.3% a year earlier due to a $271.6 million charge taken in fiscal Q2 2026 to settle litigation in the fertility business.
💸 Management expects approximately $272 million in litigation-related payments and $170 million in free cash flow for fiscal Q4, excluding these costs.
📉 Net debt stood at $2.39 billion as of July 31, 2026, representing 19.9% of the company's market value when netted against cash.
👷 Management plans to hire more salespeople in the U.S. to address a workforce that is smaller than its competitors'.
📈 Bullish signals
📈Cooper Companies produced free cash flow equal to 5.6% of its market value over the last twelve months, significantly higher than the 4.2% median for S&P 500 companies.
📈The company generated $678 million in free cash flow over the twelve months to July 31, 2026, up from $189 million two years earlier.
📈Fiscal Q3 delivered the highest quarterly free cash flow in Cooper's history, driven by stronger operations and lower capital spending.
📈Free cash flow has remained above zero in every twelve-month period since July 2023, demonstrating consistent operational cash generation.
💸Management aims for $2.2 billion of free cash flow across fiscal 2026 to 2028 despite plans to borrow more capital.
📉 Risk factors
📉Cooper's shares lost 13.3% over the past year while the S&P 500 returned 12.2%, indicating a significant market underperformance.
📉CooperVision's fiscal Q3 2026 revenue was essentially flat from a year earlier, with management cutting its organic growth forecast to 1.5% at the midpoint.
⚖️Operating margins fell to 12.8% from 18.3% a year earlier due to a $271.6 million charge taken in fiscal Q2 2026 to settle litigation.
💸Management expects roughly $272 million of free cash flow payments related to litigation in fiscal Q4, weighing on near-term cash.
📉Net debt stood at $2.39 billion as of July 31, 2026, representing 19.9% of the company's market value.
Article
Cooper Companies (COO) has generated significant free cash flow, producing 5.6% of its market value over the last twelve months compared to a 4.2% median for S&P 500 companies. Despite this strong cash generation, the stock price has underperformed the broader market, losing 13.3% over the past year while the S&P 500 gained 12.2%. Management attributes the low valuation to expectations of a shrinking business or high litigation costs, though recent data suggests the underlying cash flow remains robust.
The company operates through two main segments: CooperVision, which sells contact lenses, and CooperSurgical, which provides fertility and surgical products. Over the twelve months ending July 31, 2026, the business produced $678 million in free cash flow, a substantial increase from $189 million two years prior. This cash flow represented 16.0% of total revenue, with management noting that fiscal Q3 delivered the highest quarterly free cash flow in the company's history due to improved operations and lower capital spending.
However, growth concerns persist specifically within the contact lens division. CooperVision's revenue was essentially flat year-over-year in fiscal Q3 2026, leading management to cut its organic growth forecast for fiscal 2026 to 1.5% from a previous expectation of 4.0%. The slowdown is attributed to inventory adjustments and the phasing out of older hydrogel lenses. Additionally, operating margins declined to 12.8% from 18.3% a year earlier due to a significant $271.6 million charge taken in fiscal Q2 2026 to settle litigation in its fertility business.
Looking ahead, Cooper expects to face substantial cash outflows in fiscal Q4, including approximately $272 million in litigation-related payments and $170 million in free cash flow before those costs. The company has increased borrowing to fund these payments and share buybacks, with net debt standing at $2.39 billion as of July 31, 2026. Investors are advised to watch for the December 2026 earnings report, which will provide critical updates on CooperVision's organic growth trajectory and free cash flow performance after accounting for the anticipated litigation expenses.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Cooper Companies (COO) has generated significant free cash flow, producing 5.6% of its market value over the last twelve months compared to a 4.2% median for S&P 500 companies. Despite this strong cash generation, the stock price has underperformed the broader market, losing 13.3% over the past year while the S&P 500 gained 12.2%. Management attributes the low valuation to expectations of a shrinking business or high litigation costs, though recent data suggests the underlying cash flow remains robust.
The company operates through two main segments: CooperVision, which sells contact lenses, and CooperSurgical, which provides fertility and surgical products. Over the twelve months ending July 31, 2026, the business produced $678 million in free cash flow, a substantial increase from $189 million two years prior. This cash flow represented 16.0% of total revenue, with management noting that fiscal Q3 delivered the highest quarterly free cash flow in the company's history due to improved operations and lower capital spending.
However, growth concerns persist specifically within the contact lens division. CooperVision's revenue was essentially flat year-over-year in fiscal Q3 2026, leading management to cut its organic growth forecast for fiscal 2026 to 1.5% from a previous expectation of 4.0%. The slowdown is attributed to inventory adjustments and the phasing out of older hydrogel lenses. Additionally, operating margins declined to 12.8% from 18.3% a year earlier due to a significant $271.6 million charge taken in fiscal Q2 2026 to settle litigation in its fertility business.
Looking ahead, Cooper expects to face substantial cash outflows in fiscal Q4, including approximately $272 million in litigation-related payments and $170 million in free cash flow before those costs. The company has increased borrowing to fund these payments and share buybacks, with net debt standing at $2.39 billion as of July 31, 2026. Investors are advised to watch for the December 2026 earnings report, which will provide critical updates on CooperVision's organic growth trajectory and free cash flow performance after accounting for the anticipated litigation expenses.
📈 Cooper generated $678M free cash flow, up from $189M two years prior.
📉 Stock fell 13.3% despite 5.6% yield while underperforming the S&P 500.
⚖️ Operating margins dropped to 12.8% due to a $271.6M fertility litigation charge.
💸 Company expects $272M in litigation payments and $170M Q4 free cash flow.
👷 Management plans U.S. sales hires to address workforce size gaps vs competitors.
📈 Cooper Companies generated $678 million in free cash flow over the twelve months to July 31, 2026, representing a significant increase from $189 million two years prior.
📉 The stock price has declined 13.3% over the past year despite producing a 5.6% free cash flow yield, underperforming the S&P 500 which returned 12.2%.
📉 CooperVision's fiscal Q3 2026 revenue was flat year-over-year at $717 million, prompting management to cut its organic growth forecast for fiscal 2026 to 1.5%.
⚖️ Operating margins fell to 12.8% from 18.3% a year earlier due to a $271.6 million charge taken in fiscal Q2 2026 to settle litigation in the fertility business.
💸 Management expects approximately $272 million in litigation-related payments and $170 million in free cash flow for fiscal Q4, excluding these costs.
📉 Net debt stood at $2.39 billion as of July 31, 2026, representing 19.9% of the company's market value when netted against cash.
👷 Management plans to hire more salespeople in the U.S. to address a workforce that is smaller than its competitors'.
Bullish Signals
FCF was 5.6% of market value vs 4.2% S&P 500 median.
Generated $678M FCF in twelve months to July 31, 2026.
Q3 set record FCF driven by stronger operations and lower capex.
FCF stayed positive every twelve-month period since July 2023.
Targets $2.2B FCF for fiscal 2026-2028 despite borrowing plans.
Risk Factors
Shares lost 13.3% vs S&P 500's 12.2% gain.
Revenue flat; organic growth forecast cut to 1.5%.
Margins fell to 12.8% due to $271.6M charge.
Litigation payments of $272M weigh on near-term cash.
Net debt is $2.39B, 19.9% of market value.
Bullish Signals
Cooper Companies produced free cash flow equal to 5.6% of its market value over the last twelve months, significantly higher than the 4.2% median for S&P 500 companies.
The company generated $678 million in free cash flow over the twelve months to July 31, 2026, up from $189 million two years earlier.
Fiscal Q3 delivered the highest quarterly free cash flow in Cooper's history, driven by stronger operations and lower capital spending.
Free cash flow has remained above zero in every twelve-month period since July 2023, demonstrating consistent operational cash generation.
Management aims for $2.2 billion of free cash flow across fiscal 2026 to 2028 despite plans to borrow more capital.
Risk Factors
Cooper's shares lost 13.3% over the past year while the S&P 500 returned 12.2%, indicating a significant market underperformance.
CooperVision's fiscal Q3 2026 revenue was essentially flat from a year earlier, with management cutting its organic growth forecast to 1.5% at the midpoint.
Operating margins fell to 12.8% from 18.3% a year earlier due to a $271.6 million charge taken in fiscal Q2 2026 to settle litigation.
Management expects roughly $272 million of free cash flow payments related to litigation in fiscal Q4, weighing on near-term cash.
Net debt stood at $2.39 billion as of July 31, 2026, representing 19.9% of the company's market value.
William Blair analyst Margaret Kaczor upgraded Cooper Companies, Inc. (NASDAQ: COO) to a Buy rating following the release of its fiscal Q2 2025 results on May 29. The company exceeded market expectations with revenue growing 6% year-over-year to $1.002 billion and non-GAAP diluted EPS rising 14% to $0.96, driven by operating leverage from internal investments.
The analyst highlighted that the strong financial performance prompted management to raise its earnings guidance for fiscal year 2025, projecting total revenue between $4.107 billion and $4.146 billion. This represents an organic growth rate of 5% to 6%, signaling confidence in the company's ability to sustain robust mid- to high-single-digit growth through strategic initiatives.
Cooper Companies operates through two main segments: Cooper Surgical, which focuses on women's health and fertility products, and Cooper Vision, which develops medical devices for vision challenges. The analyst believes these strategic areas, including product launch acceleration and production capacity expansion, will support the company's durable growth trajectory despite conservative market expectations.
📈 William Blair upgraded COO to Buy after strong Q2 2025 results.
💰 Revenue hit $1.002 billion, up 6% year-over-year.
📊 Non-GAAP EPS reached $0.96, a 14% increase.
🚀 FY2025 revenue guidance raised to $4.107-$4.146 billion.
⚙️ Operating leverage and strategic initiatives drive margin expansion.
📈 William Blair analyst Margaret Kaczor upgraded Cooper Companies (COO) to a Buy rating following strong fiscal Q2 2025 results released on May 29.
💰 The company reported $1.002 billion in revenue, representing a 6% year-over-year increase compared to the prior period.
📊 Non-GAAP diluted earnings per share reached $0.96, marking a 14% increase from the same quarter last year.
🚀 Management raised its fiscal year 2025 revenue guidance to a range of $4.107 billion to $4.146 billion.
📈 The company projects organic revenue growth of 5% to 6% for the upcoming fiscal year.
⚙️ Strong operating leverage from internal investments is driving the improved financial performance and margin expansion.
🔬 Cooper Companies operates through two segments: Cooper Surgical focusing on women's health and Cooper Vision addressing various vision challenges.
🌍 Strategic initiatives include product launch acceleration, production capacity expansion, and geographical expansion to support growth.
💡 Analysts view the company as poised for durable mid- to high-single-digit growth supported by its strategic positioning.
Bullish Signals
Upgraded to Buy on strong fiscal Q2 2025 results.
Bullish Signals
William Blair analyst Margaret Kaczor upgraded Cooper Companies (COO) to a Buy rating following strong fiscal Q2 2025 results.
The company exceeded expectations with revenue growing 6% year-over-year to $1.002 billion in the second quarter of fiscal 2025.
Non-GAAP diluted earnings per share increased 14% to $0.96, demonstrating strong profitability and operational efficiency.
Management raised its full-year fiscal 2025 revenue guidance to a range of $4.107 billion to $4.146 billion.
The company projects organic revenue growth of 5% to 6% for fiscal year 2025, indicating sustainable business expansion.
Strong operating leverage from internal investments is driving improved financial performance and margin expansion.
Strategic initiatives including product launch acceleration and production capacity expansion support durable mid- to high-single-digit growth.
The Cooper Companies (COO) shares dropped approximately 15% to a 52-week low near $51 following the abandonment of a strategic review for its CooperSurgical unit. Management ended the nine-month auction process in December 2025, citing that bids received did not reflect shareholder interests due to temporary headwinds like new competition and litigation expenses. Despite the failed sale, the board authorized a new $1 billion share repurchase program to signal confidence.
The core issue remains performance at CooperVision, the company's primary contact lens business, which posted flat organic revenue growth in the third quarter. To normalize channel inventory ahead of fiscal 2027, the firm initiated a reduction in U.S. channel stock, contributing to a lowered outlook. However, free cash flow for the quarter hit a record $273 million, expanding financial flexibility despite the operational slowdown.
Analyst sentiment is mixed regarding the valuation and future trajectory. Bank of America noted that the lack of a deal suggests buyers' unwillingness to meet management's valuation, leaving shareholders exposed to headwinds. Conversely, institutional interest showed a modest increase with 52 hedge funds holding the stock in Q2 2026 compared to 49 previously. The article concludes that if distributor destocking concludes smoothly and surgical pressures abate, the current low valuation supports accumulation.
📉 Shares dropped ~15% after abandoning CooperSurgical auction near $51 low.
💰 Management authorized new $1 billion share repurchase program.
👁️ Flat organic revenue growth at core contact lens business triggered cut.
📦 Company reduced U.S. channel inventory for fiscal 2027 foundation.
💵 Record Q3 free cash flow of $273 million expanded flexibility.
📉 Shares cratered ~15% to a 52-week low near $51 after the company abandoned its nine-month auction for CooperSurgical.
💰 Management authorized a new $1 billion share repurchase program to signal conviction despite the failed sale.
👁️ Flat organic revenue growth at the core CooperVision contact lens business triggered the guidance cut.
📦 The company initiated a reduction of U.S. channel inventory to establish a healthier foundation for fiscal 2027.
💵 Record free cash flow of $273 million in Q3 expanded financial flexibility despite operational headwinds.
🏛️ Bank of America highlighted that the failed auction indicates buyers' unwillingness to meet management's valuation.
📊 Institutional interest increased slightly, with 52 hedge funds holding COO in Q2 2026 versus 49 in Q1.
⚖️ The stock trades at 18 times earnings, down roughly 40% from its high, raising questions about value trap status.
Company updateLeadership changeAI-generated analysis
Cooper Companies (COO) is navigating a significant leadership transition following the departure of President and CEO Albert White, with Board member Walter Rosebrough stepping in as executive chair to oversee daily operations. Despite this structural change, recent trading data indicates investor caution, evidenced by a 16.57% decline over the past 90 days and a 13.69% drop in total shareholder return over one year, even though the stock has gained 6.74% in the last month.
Analysts view Cooper Companies as a quality healthcare player currently undervalued at approximately $60.34, with a calculated fair value of $66.21 based on projected cash generation and its premium lens focus. The company is executing operational streamlining initiatives, including shared services, restructuring, and AI-enabled inventory optimization, which contributed to record free cash flow in Q3 2026.
Management has reiterated guidance for roughly US$2.2 billion in free cash flow over the 2026 to 2028 period, creating potential for improved working capital efficiency and stronger net margins. However, bulls and bears remain divided on the stock's trajectory, with concerns lingering regarding softness in the Asia Pacific region, legacy hydrogel rationalization challenges, and potential escalation of legal issues involving its CooperSurgical division.
👔 Walter Rosebrough assumes executive chair as Albert White steps down.
📉 Stock declined 16.57% over past 90 days reflecting investor caution.
💰 Reported record Q3 free cash flow with $2.2B guidance through 2028.
🚀 Implementing operational streamlining and AI inventory optimization to boost efficiency.
⚖️ Faces risks from Asia Pacific softness and CooperSurgical legal issues.
👔 Cooper Companies is undergoing a leadership change as Albert White steps down as CEO and Walter Rosebrough assumes the role of executive chair.
📉 The stock has declined 16.57% over the past 90 days and 13.69% in total shareholder return over one year, reflecting investor caution despite recent gains.
💰 Cooper Companies reported record free cash flow in Q3 2026 and reiterated guidance for approximately US$2.2 billion in free cash flow from 2026 to 2028.
🚀 The company is implementing operational streamlining efforts including shared services, restructuring, and AI-enabled inventory optimization to boost efficiency.
💎 Analysts calculate a fair value of $66.21 for Cooper Companies, suggesting the current price of $60.34 may be undervalued relative to projected cash generation.
🌏 Investors are concerned about ongoing softness in the Asia Pacific region which could continue to drag on the company's results.
⚖️ The stock faces specific risks related to legacy hydrogel rationalization and potential escalation of legal issues involving its CooperSurgical division.
Bullish Signals
Record Q3 2026 free cash flow shows strong financial performance.
Management guides US$2.2B FCF for 2026-2028 supporting growth.
Operational streamlining and AI improve working capital efficiency.
Analyst fair value $66.21 suggests upside from $60.34.
Risk Factors
Asia Pacific softness expected to drag on results.
Cooper Companies reported record free cash flow in Q3 2026, demonstrating strong underlying financial performance despite leadership changes.
Management has reiterated robust guidance for approximately US$2.2 billion in free cash flow over the 2026 to 2028 period, supporting future growth expectations.
The company is actively streamlining operations through shared services, restructuring, and AI-enabled inventory optimization to improve working capital efficiency.
Analysts assign a fair value of $66.21 to the stock, indicating that the current price of $60.34 may not fully reflect its projected cash generation and premium lens focus.
Risk Factors
The company faces ongoing softness in the Asia Pacific region which is expected to continue dragging on its results.
Legacy hydrogel rationalization efforts present a risk that could impact the company's financial performance in the near term.
The Cooper Companies, Inc. (COO) is preparing to release its Q4 2026 earnings report. The San Ramon-based firm operates through two segments, CooperVision and CooperSurgical, developing and marketing contact lenses for various vision challenges. Analysts project the company's diluted EPS for this quarter to be $1.07, representing a 7% decline from the year-ago quarter of $1.15.
Looking ahead to fiscal 2026, analysts forecast COO's EPS to reach $4.53, an increase of 10% from the previous year's $4.12. For fiscal 2027, earnings are expected to rise further by approximately 3.5% year-over-year to $4.69. Despite these forward-looking projections, the stock has underperformed significantly over the past 52 weeks.
COO shares have declined 17.2% over the last year, trailing the S&P 500's 12.4% gain and the State Street Healthcare Select Sector SPDR ETF's 23.6% rise during the same period. Analysts cite tepid demand and below-average sales growth as primary concerns, with annual sales growth hovering near 6.5% over the past two years, which is lower than the industry average for healthcare companies.
📅 COO to release Q4 2026 earnings report soon.
💰 Analysts expect diluted EPS of $1.07, down 7%.
📈 Fiscal 2026 EPS projected at $4.53, up 10%.
📉 Stock fell 17.2% over past 52 weeks.
🏆 Exceeded Wall Street EPS estimates for last four quarters.
📅 The Cooper Companies (COO) is set to release its Q4 2026 earnings report soon.
💰 Analysts expect diluted EPS of $1.07 for the upcoming quarter, down 7% from $1.15 in the prior year.
📈 Fiscal 2026 EPS is projected at $4.53, reflecting a 10% increase from fiscal 2025 levels.
📉 COO stock has fallen 17.2% over the past 52 weeks, underperforming both the S&P 500 and the healthcare sector ETF.
📊 Annual sales growth has averaged nearly 6.5% over the last two years, falling below the industry average.
🔮 Sales growth is estimated at 4.2% for the next year, indicating weaker demand than recent history.
💼 Management faces criticism for returns on capital that are below average, suggesting limited investment opportunities.
🏆 The company has exceeded Wall Street's EPS estimates in each of its last four quarters.
👥 Among 18 analysts covering the stock, the consensus rating is 'Hold' with a price target of $65.25.
Bullish Signals
Exceeded EPS estimates for four consecutive quarters.
Analysts project 2026 EPS of $4.53.
Risk Factors
Stock declined 17.2% over past 52 weeks.
Sales growth of 6.5% trails industry average.
Next year's estimated sales growth is 4.2%.
Returns on capital are below average.
Bullish Signals
The company has successfully exceeded Wall Street's EPS estimates in each of its last four quarters.
Analysts project fiscal 2026 EPS to reach $4.53, marking a 10% increase from the previous year.
Risk Factors
COO stock has declined 17.2% over the past 52 weeks, significantly underperforming the S&P 500 and healthcare sector peers.
Annual sales growth of nearly 6.5% over the past two years is below the industry average for healthcare companies.
Estimated sales growth of 4.2% for the next year indicates tepid demand, lower than performance in the last two years.
The company's returns on capital are below average, indicating a lack of compelling investment opportunities for management.
The Cooper Companies, Inc. (NASDAQ:COO) shares tumbled 14.61% on Friday, marking a third consecutive day of declines as investors reacted negatively to the company's lowered guidance for fiscal year 2025. Management revised its organic growth outlook down to a range of 5% to 6%, missing the previously targeted 6% to 8% expansion rate.
Following the earnings announcement, major Wall Street analysts reduced their bullish stance on the medical device manufacturer. JPMorgan cut its rating from 'overweight' to 'neutral' and lowered its price target significantly from $110 to $76, citing mixed execution over recent quarters and concerns about a potential durable slowdown in market trends.
Wells Fargo also participated in the sell-off by reducing its price target for COO from $118 to $93. The consensus among analysts suggests that the company faces headwinds related to its core business performance, leading to a broader reassessment of its valuation and future growth prospects despite its position in the medical device sector.
📉 COO shares fell 14.61% to close at $68.28 after three losing days.
📉 FY2025 organic growth guidance lowered to 5-6% from prior 6-8% target.
📉 JPMorgan downgraded stock to 'neutral' with price target cut to $76.
📉 Wells Fargo reduced price target from $118 to $93 due to weak outlook.
⚠️ Concerns stem from mixed execution and potential market trend slowdowns.
📉 COO shares dropped 14.61% on Friday, extending a three-day losing streak to close at $68.28.
📉 The company lowered its FY2025 organic growth guidance to 5-6%, down from the prior target of 6-8%.
📉 JPMorgan downgraded COO to 'neutral' with a new price target of $76, reduced from $110.
📉 Wells Fargo cut its price target for The Cooper Companies from $118 to $93 following the weak outlook.
⚠️ Analysts cited mixed execution over several quarters and potential market trend slowdowns as key concerns.
Risk Factors
Shares fell 14.61% on Friday amid weak sentiment.
FY2025 growth guidance cut to 5-6% from 6-8%.
JPMorgan downgraded stock and slashed target to $76.
Wells Fargo lowered price target from $118 to $93.
Risk Factors
Shares fell 14.61% on Friday, marking a third consecutive day of declines driven by weak investor sentiment.
The company reduced its FY2025 organic growth guidance to 5-6%, missing the previously targeted range of 6-8%.
JPMorgan downgraded the stock from 'overweight' to 'neutral' and slashed its price target from $110 to $76.
Wells Fargo lowered its price target for COO from $118 to $93 following the earnings announcement.
Cooper Companies (COO) stock has recently climbed despite weak longer-term returns and a 40.8% share price decline over the past five years, prompting an analysis of whether current valuations align with earnings. The article highlights that recent reports indicate flat revenue, though management is focusing on profitable growth and cash flow generation.
Valuation metrics suggest COO trades at approximately 20.6x earnings, which is below the Medical Equipment industry average of 27.0x and lower than the peer group average of 24.8x. Analysts note that despite legal investigations and softer guidance cooling enthusiasm, the P/E multiple remains discounted relative to a blended fair value model accounting for margins and scale.
Simply Wall St presents two divergent narratives: a bull case citing 7% undervaluation driven by operational streamlining, record Q3 2026 free cash flow, and reiterated guidance of roughly US$2.2b in free cash flow for 2026-2028; and a bear case suggesting 6% overvaluation due to the transition away from older hydrogel products in Asia Pacific weighing on revenue mix.
The article concludes that while demand for daily silicone hydrogel lenses supports solid contact lens revenue, future performance depends on execution of restructuring efforts and AI-enabled inventory optimization. The debate centers on whether the market has adequately priced in the potential for improved working capital efficiency and higher free cash flow yields amidst ongoing legal scrutiny.
📉 Shares down 40.8% in five years despite recent price climbs.
💰 Trades at 20.6x earnings, below industry average of 27.0x.
📈 Management prioritizes profitable growth after flat late 2026 revenue.
📉 Cooper Companies shares have fallen 40.8% over the past five years despite recent price climbs, creating a valuation reset opportunity.
💰 The stock trades at roughly 20.6x earnings, significantly below the Medical Equipment industry average of 27.0x and peer group average of 24.8x.
📈 Management is focusing on profitable growth and cash flow following reports of flat revenue in late 2026.
⚖️ Legal investigations and softer guidance have cooled investor enthusiasm, yet the P/E multiple remains below analyst fair value models.
💵 Bull case narrative identifies record Q3 2026 free cash flow and reiterated guidance for US$2.2b annualized FCF (2026-2028) as drivers of a 7% undervaluation.
📉 Bear case narrative warns that the transition away from older hydrogel products in Japan and Asia Pacific could weigh on overall CooperVision revenue mix, suggesting 6% overvaluation.
🤖 Company-wide efforts to streamline operations through shared services, restructuring, and AI-enabled inventory optimization aim to improve working capital efficiency.
👁️ Community sentiment is split between investors who see premium lenses and cash flow as underappreciated versus those believing expectations remain too generous.
Bullish Signals
P/E of 20.6x is below industry average of 27.0x.
Recorded record free cash flow in Q3 2026.
Reiterated guidance for US$2.2b free cash flow through 2028.
Cooper Companies trades at a P/E of roughly 20.6x, which is below the Medical Equipment industry average of 27.0x and the peer group average of 24.8x.
The company recorded record free cash flow in Q3 2026 and reiterated guidance for approximately US$2.2b of free cash flow over the 2026 to 2028 period.
Management is executing company-wide efforts to streamline operations through shared services, restructuring, and AI-enabled inventory optimization to improve working capital efficiency.
Strong demand for daily silicone hydrogel lenses and premium products like MyDay multifocal and Energys is currently supporting solid contact lens revenue.
Risk Factors
Ongoing legal investigations and softer guidance have clearly cooled investor enthusiasm regarding the company's stock.
The transition away from older hydrogel products in Japan and other parts of Asia Pacific could weigh on the overall CooperVision revenue mix.
Recent reports indicate flat revenue, requiring investors to carefully assess how fast earnings can improve relative to current share price pressure.
Business restructuringShare buybackAI-generated analysis
The Cooper Companies (COO) has concluded its strategic review process, deciding to retain its CooperSurgical unit rather than sell it. The Board determined that the valuation offers received were not in shareholders' best interest and acknowledged temporary drivers affecting the unit's valuation gap.
Despite retaining CooperSurgical, the company faces near-term headwinds with marginal top-line growth of 1% year-over-year in the third quarter. Adjusted diluted EPS rose 4% to $1.15, but adjusted gross margins contracted by 60 basis points due to higher manufacturing costs and currency fluctuations.
To support shareholder value amidst these challenges, Cooper Companies expanded its share repurchase program from $2 billion to $3 billion after executing $445 million in buybacks during the fiscal year. Management also plans operational improvements, including growing the global sales organization for CooperVision and implementing cost-cutting measures.
🏛️ Board retained CooperSurgical unit after rejecting unsuitable sale offers.
💰 Expanded share repurchase program from $2B to $3B total.
📈 Adjusted diluted EPS rose 4% YoY to $1.15 despite flat top-line.
📉 Gross margins declined 60 bps due to higher manufacturing costs.
🚀 Plans global sales expansion for CooperVision segment to drive revenue.
🏛️ The Board unanimously decided to retain the CooperSurgical unit after rejecting sale offers deemed not in shareholders' best interest.
💰 The company expanded its share repurchase program from $2 billion to $3 billion following $445 million in buybacks executed this fiscal year.
📈 Adjusted diluted EPS increased 4% year-over-year to $1.15, reflecting a 4% jump from Q3 FY25 despite marginal top-line growth.
📉 Adjusted gross margins declined by 60 basis points compared to the prior year due to higher manufacturing costs and currency fluctuations.
👁️ CooperVision segment delivered flat organic growth hindered by challenges in the Asia Pacific and Americas regions.
🔍 The sphere and other lens category within CooperVision declined 1% organically year-over-year during the third quarter.
🚀 Management plans to grow the global sales and marketing organization for CooperVision to drive future revenue expansion.
✂️ The company is prioritizing cost-cutting measures, efficiency initiatives, and revised inventory and logistics programs.
📊 Institutional interest remains steady with 52 hedge funds holding positions as of Q2 2026, up from 49 in the previous quarter.
🏦 BlackRock remains the largest institutional investor, owning 7.71% of outstanding shares.
Bullish Signals
Board retained CooperSurgical unit as sale offers were insufficient.
Risk Factors
Adjusted gross margins contracted 60 bps due to costs.
Activist investor Jana Partners is intensifying its campaign against the Cooper Companies (NASDAQ: COO), urging the board to sell off non-core divisions and replace CEO Albert White. In a recent letter, Jana criticized management for problematic forecasting, serial negative surprises, and poor capital allocation, specifically citing the company's lowered 2026 growth guidance from approximately 4% down to a range of 2% to 3%. The activist also highlighted concerns regarding flat revenue in the CooperVision segment despite significant capital investments made between 2023 and 2024.
Cooper Companies recently completed an internal review of its CooperSurgical division, with the board unanimously deciding to retain the business rather than sell it. CEO Albert White explained that offers received for the unit did not reflect its true value, noting that temporary market factors such as new competitive entrants in the non-hormonal IUD market and a fertility litigation settlement influenced valuations. Despite activist pressure to divest, the company maintains its strategic position on holding onto CooperSurgical.
To address shareholder concerns regarding capital efficiency, the company announced an expansion of its stock buyback program from $2 billion to $3 billion. This move follows the repurchase of $445 million in shares during the current fiscal year. While Jana Partners has also called for a new board chair and directors, another activist group, Browning West, previously urged the company to restructure as a pure-play vision care provider, highlighting ongoing governance tensions.
📉 Jana Partners demands CEO replacement and division sales due to poor capital allocation.
📉 2026 growth forecast lowered from 4% to 2%-3% citing forecasting history issues.
💰 Stock buyback program expanded to $3 billion after $445M repurchased this year.
🛡️ Board retained CooperSurgical division, rejecting external offers as insufficient and risky.
👁️ CooperVision revenue flat at $717M despite $750M capital investments in 2023-2024.
📉 Activist investor Jana Partners is lobbying Cooper Companies (NASDAQ: COO) to sell divisions and replace CEO Albert White following criticism of poor capital allocation.
📉 The company lowered its 2026 annual growth forecast from roughly 4% to a range between 2% and 3%, citing problematic forecasting history.
💰 Cooper Companies expanded its stock buyback program from $2 billion to $3 billion after repurchasing $445 million in shares this fiscal year.
🛡️ The board unanimously voted to retain the CooperSurgical division, rejecting external offers deemed insufficient due to competitive and litigation factors.
👁️ Revenue for the CooperVision segment remained largely flat at $717.0 million despite approximately $750 million in capital investments between 2023 and 2024.
📈 CooperSurgical reported third-quarter sales of $349.2 million, representing a 2% growth compared to the same period last year.
⚖️ Activist Jana Partners criticized management for serial negative surprises and expectation mismanagement in recent earnings reports.
🔄 Another activist group, Browning West, previously urged the company to restructure as a pure-play vision care provider.
Bullish Signals
Stock buyback program expanded from $2B to $3B.
Board retained CooperSurgical division after rejecting low offers.
Risk Factors
Jana Partners criticized poor forecasting, negative surprises, and capital allocation.
2026 growth forecast lowered from 4% to 2-3% range.
CooperVision revenue flat at $717M despite $750M capital investment.
Bullish Signals
Cooper Companies expanded its stock buyback program from $2 billion to $3 billion following the repurchase of $445 million in shares this fiscal year.
The board unanimously voted to retain the CooperSurgical division, rejecting external offers that management deemed insufficient relative to the unit's value.
Risk Factors
Activist investor Jana Partners criticized the company for problematic forecasting, serial negative surprises, and poor capital allocation in a recent letter to the board.
The company lowered its 2026 annual growth forecast from approximately 4% down to a range between 2% and 3%, signaling reduced business momentum.
Revenue for the CooperVision segment remained largely flat at $717.0 million despite the company investing approximately $750 million in capital between 2023 and 2024.
Cooper Companies (COO) stock remains stable near its recent trading range as investors assess the company ahead of an upcoming earnings update. The market is weighing the firm's steady revenue growth against current valuation levels and sector competition, with shares trading within their established 52-week corridor on the New York Stock Exchange.
The company operates through two primary segments: CooperVision, focused on vision care products like contact lenses, and CooperSurgical, specializing in women's health and fertility devices. Recent financial performance shows group revenue growth driven by daily disposable and specialty lenses, with operating income and earnings per share improving year-over-year despite varying margin dynamics across segments.
Guidance for the current fiscal year points to continued revenue expansion, leveraging stable demand in developed markets and growth potential in emerging regions. Analysts view Cooper as a blend of defensive vision care qualities and cyclical women's health opportunities, with forward price-to-earnings multiples reflecting a premium valuation justified by consistent growth execution.
Key opportunities include expanding market share in contact lenses supported by demographic trends and technological advances, while risks involve currency fluctuations and input cost inflation that could compress margins. Investors are closely monitoring the upcoming quarterly report for confirmation of sustainable profit growth and effective management of these external pressures.
📈 Stock trades stable near recent closing levels with ample liquidity.
👁️ Vision care segment drives revenue via daily and specialty lenses.
🏥 Surgical division offers cyclical growth in women's health and fertility.
💰 Group revenue grew mid- to high-single-digits versus prior-year quarter.
📉 Forward P/E sits low-mid twenties, trading at a premium to peers.
📈 Cooper Companies stock trades in a stable range near recent closing levels with liquidity sufficient for active investors.
👁️ The company's vision care segment, CooperVision, drives revenue growth through daily disposable and specialty contact lenses.
🏥 CooperSurgical focuses on women's health, fertility, and related medical devices providing cyclical growth exposure.
💰 Group revenue achieved mid- to high-single-digit percentage increases compared to the prior-year quarter.
📊 Operating income and earnings per share improved year-on-year despite varying margin dynamics by segment.
🔮 Guidance indicates continued revenue growth with a focus on expanding the addressable market for contact lenses.
🌍 Demand is supported by stable markets in developed regions and incremental growth in emerging regions.
📉 Forward price-to-earnings ratio sits in the low- to mid-twenties, placing the stock at a premium to peers.
💹 Currency movements and cost inflation pose risks that could affect reported figures and compress margins.
🎯 Analyst consensus views Cooper as offering a blend of growth and resilience within the health care sector.
Bullish Signals
Revenue grew driven by daily disposable and specialty lenses.
Risk Factors
Margins vary due to input costs and sales/marketing investments.
Currency moves could reduce translated USD revenue amounts.
High manufacturing/logistics costs may compress margins without efficiency gains.
Stock trades at a premium forward multiple vs peers.
Bullish Signals
Cooper Companies delivered revenue growth at the group level driven primarily by its portfolio of daily disposable and specialty lenses.
The company reported year-on-year improvements in operating income and earnings per share despite varying margin dynamics.
Guidance points to continued revenue growth with a strategic focus on expanding the addressable market for contact lens offerings.
Demographic trends including aging populations and increased screen time support sustained demand for vision correction products.
Technological advances in lens materials and designs offer potential for mix improvements and enhanced pricing power.
Risk Factors
Margin dynamics varied by segment due to input costs and investment in sales and marketing, requiring close monitoring.
Currency movements could reduce translated United States dollar amounts if a significant portion of revenue is generated outside the US.
Higher manufacturing and logistics costs can compress margins if not offset by efficiency gains or price adjustments.
The stock trades at a forward multiple in the low- to mid-twenties, which represents a premium to some diversified health care peers.
Cooper Companies (COO) reported quarterly revenue of approximately $1.07 billion, falling short of the market consensus estimate of roughly $1.10 billion. Despite beating Wall Street's adjusted earnings per share estimate of $1.12 with actual results of $1.15, the stock price dropped nearly 15% following the announcement. The decline was driven by a sharp reduction in guidance for the remainder of fiscal 2026 and a significant revenue shortfall.
Management attributed the financial underperformance entirely to a proactive decision to reduce U.S. channel inventory within its CooperVision segment. CEO Albert White explained that consumers had purchased products ahead of anticipated price increases, consolidation activity, and IT upgrades during the first half of the year, creating an inventory overhang. Consequently, the company chose to destock rather than maintain current growth levels tied to consumption.
Levi & Korsinsky has launched a securities investigation into Cooper Companies regarding these disclosures. The firm is examining whether investors were appropriately informed about the growing inventory overhang and the risks associated with the intentional, proactive destocking strategy before the corrective disclosure caused the stock price to decline.
📉 Revenue missed estimates at $1.07 billion vs $1.10 billion consensus.
📊 Adjusted EPS beat expectations at $1.15 per share.
📉 Stock dropped 15% on revenue miss and reduced guidance.
⚖️ Levi & Korsinsky investigates misleading demand and inventory statements.
📉 Cooper Companies reported quarterly revenue of $1.07 billion, missing the market consensus estimate of approximately $1.10 billion.
📊 The company beat adjusted earnings expectations with $1.15 per share against a consensus of $1.12 per share.
📉 Stock price fell nearly 15% immediately following the announcement of the revenue shortfall and reduced guidance.
🏭 Management attributed the entire guidance reduction to proactive destocking of U.S. channel inventory in the CooperVision segment.
💬 CEO Albert White stated consumers bought inventory ahead of price increases, consolidation, and IT upgrades during the first half of the year.
⚖️ Levi & Korsinsky is investigating whether Cooper Companies made misleading statements regarding demand trends and inventory levels.
📅 The investigation concerns statements made prior to a corrective disclosure that allegedly caused investors to purchase at inflated prices.
Bullish Signals
Earnings beat estimates at $1.15 vs $1.12 consensus.
Reduced U.S. channel inventory to boost consumption trends.
Risk Factors
Revenue missed consensus at $1.07B vs $1.10B.
Stock dropped 15% after sharp guidance cut.
U.S. channel destocking continues to weigh on results.
Bullish Signals
Cooper Companies topped Wall Street's adjusted earnings estimate, reporting $1.15 per share against a consensus of $1.12 per share.
The company successfully executed a strategic decision to proactively reduce U.S. channel inventory to return growth to consumption trends.
Risk Factors
Quarterly revenue of approximately $1.07 billion fell short of the market consensus estimate of approximately $1.10 billion.
The stock sold off nearly 15% on a revenue shortfall and sharply reduced guidance for the remainder of fiscal 2026.
Management disclosed that proactive destocking of U.S. channel inventory weighed on results and will continue to impact Q4.
CooperCompanies reported fiscal Q3 2026 results that missed revenue expectations, with actual revenue of USD 1.07 billion falling short of the roughly USD 1.10 billion consensus estimate. Although adjusted earnings per share of USD 1.15 exceeded analyst expectations, the company significantly lowered its full-year outlook, reducing fiscal 2026 adjusted EPS guidance to a range of USD 4.51 to USD 4.55 from a prior forecast of USD 4.58 to USD 4.66.
The revenue miss and guidance cut were primarily driven by softer demand in the CooperVision segment, specifically due to ongoing channel destocking in the United States. Management revised its full-year organic growth expectation for this key business unit to just 1% to 2%, down from more robust earlier projections, and warned that fourth-quarter organic growth could range between minus 2% and zero percent.
Following the earnings announcement, CooperCompanies stock faced a sharp sell-off, trading near USD 54 on Nasdaq, well below its 52-week high. The negative sentiment was amplified by analyst downgrades, including Piper Sandler cutting its rating from Overweight to Neutral and reducing its target price, alongside a shareholder investigation into the company's performance.
📉 Q3 2026 revenue of $1.07B missed estimates at $1.10B.
📉 Fiscal 2026 EPS guidance lowered to $4.51–$4.55 range.
👁️ CooperVision destocking drives Q4 organic growth of -2% to 0%.
📉 Stock fell near $54 after Piper Sandler downgrade and target cut.
⚖️ Shareholder investigation launched over revenue shortfall and stock decline.
📉 CooperCompanies Q3 2026 revenue of USD 1.07 billion missed Wall Street estimates of roughly USD 1.10 billion.
📉 Management lowered fiscal 2026 adjusted EPS guidance to USD 4.51–4.55, down from a prior forecast of USD 4.58–4.66.
👁️ Revenue miss driven by CooperVision segment destocking, with Q4 organic growth expected between minus 2% and zero percent.
📉 Stock price fell sharply to near USD 54 on Nasdaq following the earnings report and guidance cut.
📉 Piper Sandler downgraded the stock from Overweight to Neutral and cut its target price from USD 86.00 to USD 59.00.
⚖️ A shareholder investigation was launched regarding the company's quarterly revenue shortfall and subsequent stock decline.
📉 The company authorized a USD 3.00 billion share-repurchase program covering up to roughly 22.7% of outstanding shares.
Bullish Signals
EPS beat consensus at USD 1.15 in Q3 2026.
Authorized USD 3.00B buyback covering ~22.7% of shares.
Risk Factors
Q3 2026 revenue of USD 1.07B missed expectations.
Guidance cut to USD 4.51–4.55 from USD 4.58–4.66.
CooperVision segment faces destocking pressure, growth minus 2% to 0%.
Piper Sandler downgraded stock and reduced target price.
Shareholder investigation initiated after revenue miss.
Bullish Signals
CooperCompanies adjusted EPS of USD 1.15 per share came in modestly above analyst consensus expectations for Q3 2026.
The company authorized a substantial USD 3.00 billion share-repurchase program covering up to roughly 22.7% of outstanding shares.
Risk Factors
Fiscal Q3 2026 revenue of USD 1.07 billion missed expectations, triggering a double-digit share-price slide.
Management cut full-year fiscal 2026 adjusted earnings guidance to USD 4.51–4.55 per share from a prior forecast of USD 4.58–4.66.
CooperVision segment faces destocking pressure, with Q4 organic growth expected to range between minus 2% and zero percent.
Analyst Piper Sandler downgraded the stock from Overweight to Neutral and reduced its target price significantly.
A shareholder investigation was initiated following the revenue miss and subsequent decline in stock price.
The Cooper Companies, Inc. reported its fiscal Q3 2026 financial results for the quarter and nine months ended July 31, 2026, showing significant growth in profitability despite modest revenue increases. Net sales rose slightly to $1,066.2 million in the third quarter compared to the prior-year period, while gross profit improved to $711.9 million from $692.0 million.
Net income surged dramatically to $432.8 million in Q3 2026, up from $98.3 million a year ago, driven largely by a substantial $231.0 million income tax benefit recorded this quarter versus an expense of $53.6 million previously. Diluted earnings per share reached $2.24 for the quarter and $2.49 for the nine-month period, reflecting strong operational performance.
The company's balance sheet as of July 31, 2026, shows total assets increasing to $12,673.4 million. However, a notable development is the sharp rise in accrued litigation liability to $316.5 million from just $0.7 million at the end of the prior fiscal year, alongside an increase in short-term debt to $628.1 million.
Management continues to actively manage its capital structure with treasury stock holdings growing to $1,437.9 million through share repurchases over the nine-month period. The filing highlights a contrast between strong top-line growth and significant non-operating financial adjustments impacting the bottom line.
📈 Q3 net sales rose 0.6% to $1,066.2 million.
💰 Net income surged 340% to $432.8 million.
📊 Diluted EPS jumped to $2.24 from $0.49.
⚖️ Accrued litigation liability spiked to $316.5 million.
📉 Short-term debt increased significantly to $628.1 million.
📈 Q3 net sales increased to $1,066.2 million, slightly up from $1,060.3 million in the prior-year quarter.
💰 Net income surged to $432.8 million compared to $98.3 million last year, driven by a $231.0 million tax benefit.
📊 Diluted EPS reached $2.24 for the quarter ended July 31, 2026, versus $0.49 in the previous year period.
🏦 Total assets grew to $12,673.4 million as of July 31, 2026, up from $12,394.8 million a year prior.
⚖️ Accrued litigation liability rose sharply to $316.5 million as of July 31, 2026, from $0.7 million at October 31, 2025.
📉 Short-term debt increased significantly to $628.1 million from $47.8 million during the same timeframe.
🔄 Treasury stock holdings grew to $1,437.9 million reflecting active share repurchases over the nine-month period.
📈 Nine-month net sales climbed to $3,171.8 million from $3,027.3 million in the corresponding period last year.
Bullish Signals
Q3 net income surged to $432.8M vs $98.3M last year.
Risk Factors
Litigation liability jumped to $316.5M by July 2026.
Short-term debt surged to $628.1M from $47.8M.
Bullish Signals
Q3 net income surged to $432.8 million compared to $98.3 million in the same quarter last year.
Diluted EPS reached $2.24 for the quarter ended July 31, 2026, versus $0.49 in the previous year period.
Gross profit rose to $711.9 million from $692.0 million year-over-year.
Operating income improved to $222.0 million compared to $175.7 million in the same quarter last year.
Nine-month net sales climbed to $3,171.8 million from $3,027.3 million in the corresponding period last year.
Net income for the first nine months reached $485.7 million compared to $290.3 million in the prior-year period.
Risk Factors
Accrued litigation liability rose sharply to $316.5 million as of July 31, 2026, from just $0.7 million at October 31, 2025.
Short-term debt increased significantly to $628.1 million from $47.8 million during the same timeframe.
The Cooper Companies (COO) reported third-quarter fiscal 2026 results with total revenue rising 1% year-over-year to $1.066 billion, driven by a 4% increase in adjusted diluted EPS to $1.15. The company executed significant capital return programs, repurchasing approximately 4.9 million shares for $339.1 million while maintaining $1.5 billion in remaining buyback capacity following a board authorization increase from $2 billion to $3 billion.
Financial performance was bolstered by record free cash flow generation of $273.0 million, a 66% surge driven by strong operating cash flow and disciplined capital spending. GAAP gross margins expanded to 67%, aided by the absence of prior inventory write-downs, while adjusted operating margins improved 30 basis points to 26% despite currency headwinds. The fertility segment within CooperSurgical delivered notable growth, offsetting weakness in the CooperVision ophthalmic division.
Despite strong quarterly execution and a robust balance sheet, management lowered its full-year fiscal 2026 revenue guidance to a range of $4.229 billion to $4.252 billion, implying organic growth of 2% to 3%. The company reiterated its long-term free cash flow target of exceeding $2.2 billion through FY28, signaling continued commitment to profitable expansion and efficient capital deployment even as it navigates regional headwinds in the lens business.
Institutional ownership remains stable with BlackRock holding 7.71% of outstanding shares, while hedge fund interest saw a marginal increase with positions held by 52 funds at the end of Q2 2026. The stock trades with a short interest of 4%, reflecting modest active betting against the name as investors weigh the company's strategic priorities against near-term macroeconomic and currency pressures.
📈 Revenue rose 1% YoY to $1.066B; adjusted EPS jumped 4% to $1.15.
💰 Repurchased 4.9M shares for $339.1M with $1.5B remaining buyback capacity.
🚀 Free cash flow surged 66% to a record $273.0 million.
📉 CooperVision revenue missed estimates due to inventory cuts and Asia sales drop.
📉 Full-year guidance lowered to $4.229B–$4.252B, implying 2%–3% organic growth.
📈 Total revenue increased 1% year-over-year to $1.066 billion in Q3 fiscal 2026, with adjusted diluted EPS jumping 4% to $1.15.
💰 The company repurchased approximately 4.9 million shares for $339.1 million, leaving $1.5 billion in remaining buyback capacity after raising authorization to $3 billion.
🚀 Free cash flow surged 66% to a record $273.0 million, driven by $341.7 million in operating cash flow and reduced capital spending of $68.7 million.
📉 GAAP gross margins expanded to 67%, while adjusted operating margins improved 30 basis points to 26% supported by cost discipline despite currency headwinds.
🏥 The fertility segment within CooperSurgical delivered notable growth, successfully offsetting weakness in the CooperVision ophthalmic division.
📉 CooperVision revenue fell below consensus estimates due to U.S. channel inventory reductions and a 10% drop in Asia Pacific sales.
📉 Management lowered full-year fiscal 2026 revenue guidance to $4.229 billion–$4.252 billion, implying organic growth of 2% to 3%.
🎯 The company reiterated its long-term free cash flow target of exceeding $2.2 billion through FY28, aligning with strategic priorities for shareholder value.
🏦 BlackRock remains the largest institutional investor with a 7.71% stake, while hedge fund interest increased to 52 funds holding positions in Q2 2026.
Bullish Signals
Adjusted diluted EPS jumped 4% YoY to $1.15, beating projections.
Free cash flow surged 66% to record $273M.
Fertility segment drove notable revenue growth.
GAAP gross margins expanded to 67%.
Adjusted operating margins improved 30 bps to 26%.
Risk Factors
Revenue guidance lowered to $4.229B-$4.252B with 2-3% organic growth.
CooperVision revenue missed due to inventory cuts and 10% Asia sales drop.
Currency headwinds caused 60 basis point adjusted gross margin decline.
Bullish Signals
Adjusted diluted EPS jumped 4% year-over-year to $1.15, exceeding market projections and demonstrating strong profitability.
Free cash flow surged 66% to a record $273.0 million, providing substantial flexibility for capital returns and strategic investments.
The fertility segment within CooperSurgical delivered notable growth, acting as a key driver of overall revenue expansion.
GAAP gross margins expanded to 67%, reflecting improved pricing power and the absence of prior inventory write-downs.
Adjusted operating margins improved by 30 basis points to 26%, supported by effective cost discipline and productivity gains.
Risk Factors
Management lowered full-year fiscal 2026 revenue guidance to a range of $4.229 billion to $4.252 billion, implying modest organic growth of 2% to 3%.
CooperVision segment revenue fell below consensus estimates due to U.S. channel inventory reductions and a 10% drop in Asia Pacific sales.
Currency headwinds negatively impacted adjusted gross margins, causing a 60 basis point drop from the prior year's adjusted figure.
Cooper Companies (COO) shares plummeted over 15% in premarket trading after the medical device manufacturer announced disappointing third-quarter results and a strategic reversal. Investors had anticipated a potential divestiture of its CooperSurgical division, viewing it as a catalyst for a focused contact lens business or acquisition. However, the company's board unanimously decided to retain the women's healthcare unit following a strategic assessment, dashing market expectations.
Financially, the company missed third-quarter revenue guidance, reporting $1.07 billion against Wall Street's expectation of $1.10 billion. While adjusted earnings per share beat estimates at $1.15 versus $1.12, management reduced its full-year outlook for both metrics. The revised fiscal year adjusted EPS guidance stands between $4.51 and $4.55, down from the previous range of $4.58 to $4.66.
The revenue shortfall was primarily driven by a deliberate inventory drawdown in the United States for its CooperVision contact lens segment, which generated $717 million compared to $723.5 million in the prior quarter. Management indicated that these inventory challenges will persist through the fourth quarter, with projected Q4 revenue between $1.06 and $1.08 billion. Additionally, the company expanded its share buyback authorization from $2 billion to $3 billion.
📉 COO shares tumbled over 15% after disappointing quarterly results and retained CooperSurgical division.
💰 Q3 revenue hit $1.07B, missing Wall Street's $1.10B projection due to inventory drawdown.
📉 Full-year EPS guidance lowered to $4.51-$4.55 and revenue to $4.23-$4.25 billion.
💸 Adjusted EPS beat estimates at $1.15 versus consensus of $1.12 despite lower revenue.
🔄 Board kept CooperSurgical unit, eliminating hopes for a focused contact lens divestiture.
📉 Cooper Companies (COO) shares tumbled more than 15% in premarket trading after the firm announced disappointing quarterly results and decided to retain its CooperSurgical division.
💰 Third-quarter revenue reached $1.07 billion, falling short of Wall Street's $1.10 billion projection due to an intentional drawdown of U.S. distribution channel inventory.
📉 Management reduced full-year adjusted earnings per share guidance to $4.51-$4.55 and annual revenue projections to $4.23-$4.25 billion.
👁️ The CooperVision segment reported quarterly revenue of $717 million, down from $723.5 million in the previous quarter due to inventory normalization.
💸 Despite missing revenue, the company exceeded adjusted EPS estimates at $1.15 versus the consensus of $1.12.
🔄 The board unanimously determined to keep the CooperSurgical business unit, eliminating investor hopes for a divestiture that could have created a focused contact lens enterprise.
💰 Cooper expanded its share buyback authorization from $2 billion to $3 billion following the earnings announcement.
🏆 Cooper maintains the position of the second-largest contact lens producer worldwide, trailing only Johnson & Johnson's Acuvue brand.
📅 Management indicated that inventory challenges impacting the third quarter will persist through the final quarter of fiscal year 2026.
👔 KeyBanc analyst Brett Fishbin maintains a Sector Weight rating on the shares following the strategic review conclusion.
Bullish Signals
EPS beat estimates at $1.15 vs $1.12 consensus.
Buyback authorization increased from $2B to $3B.
Ranks second globally in contact lens production.
Risk Factors
Shares fell 15% after retaining CooperSurgical division.
Q3 revenue missed at $1.07B due to US inventory drawdowns.
Full-year EPS outlook cut to $4.51-$4.55 range.
Annual revenue guidance lowered to $4.23-$4.25 billion.
CooperVision revenue dropped 6% due to inventory normalization.
Bullish Signals
Cooper Companies exceeded adjusted earnings per share projections, reporting $1.15 versus the consensus estimate of $1.12.
The company expanded its share buyback authorization from $2 billion to $3 billion, signaling confidence in capital allocation.
Cooper maintains the position of the second-largest contact lens producer worldwide, trailing only Johnson & Johnson's Acuvue brand.
Risk Factors
Shares plummeted over 15% after the company decided to retain its CooperSurgical division, dashing investor expectations of a potential divestiture.
Third-quarter revenue of $1.07 billion fell short of Wall Street's $1.10 billion projection due to deliberate inventory drawdowns in the United States.
Management reduced its full-year adjusted earnings per share outlook to $4.51-$4.55, down from the previous range of $4.58-$4.66.
Annual revenue projections were lowered to $4.23-$4.25 billion from the earlier forecast of $4.29-$4.32 billion.
The CooperVision segment reported quarterly revenue of $717 million, down from $723.5 million in the previous quarter due to inventory normalization.
Management indicated that inventory challenges impacting the third quarter will persist through the fourth quarter.
Cooper Companies (NASDAQ: COO) shares dropped approximately 13.9% following its September 9 earnings report, which delivered mixed results and weak forward guidance. While the company reported adjusted earnings of $1.15 per share that beat analyst estimates, top-line revenue of $1.07 billion missed expectations. The primary driver of the stock decline was a fourth-quarter earnings forecast ranging from $1.05 to $1.09 per share, significantly below Wall Street's consensus estimate of $1.19.
The company also disappointed investors by announcing it would retain its surgical business unit, CooperSurgical, rather than selling it as previously anticipated. This decision removed a potential deal catalyst that had driven up the stock price in anticipation of a transaction. Additionally, the medical-device firm warned that destocking at U.S. contact-lens distributors for its CooperVision segment would continue to negatively impact fourth-quarter revenue.
Despite the beat on earnings per share, the combination of weak top-line growth and the decision to keep the surgical unit created a double disappointment for shareholders. Management indicated that while retaining CooperSurgical might provide short-term earnings buffering, it could make the stock less attractive in the long term compared to a potential sale. The broader market context saw the S&P 500 and Nasdaq Composite down slightly, but COO's decline was specific to its own operational and strategic news.
📉 Stock fell 13.9% after revenue miss despite beating EPS estimates.
💸 Q4 guidance of $1.05-$1.09 missed Wall Street's $1.19 estimate.
🚫 Retaining CooperSurgical disappointed investors and removed a deal catalyst.
👁️ CooperVision segment faces Q4 destocking pressure from distributors.
⚖️ Keeping surgical unit buffers earnings but may hurt long-term appeal.
📉 Cooper Companies stock fell roughly 13.9% after reporting Q3 adjusted earnings of $1.15 per share which beat estimates but missed on top-line revenue of $1.07 billion.
💸 The company provided weak fourth-quarter guidance with a forecast of $1.05 to $1.09 per share, well below the Wall Street estimate of $1.19.
🚫 Investors were disappointed by the decision to retain CooperSurgical instead of selling the unit, removing a potential deal catalyst that had driven the stock price up.
👁️ The CooperVision segment faces continued pressure in Q4 due to lower inventory levels at U.S. contact-lens distributors causing destocking issues.
⚖️ Management noted that keeping the surgical side might buffer short-term earnings but could make the company less attractive for long-term investors compared to a sale.
📅 The earnings report and strategic review were released on September 9, with stock prices reacting negatively by early morning trading on September 10, 2026.
Bullish Signals
Adjusted EPS hit $1.15, beating estimates.
Retained surgical unit buffers short-term earnings.
Risk Factors
Q4 revenue forecast missed Wall Street consensus by $0.14.
U.S. distributor destocking will hurt numbers through fiscal 2026.
Failed CooperSurgical sale removed deal catalyst, disappointing investors.
Bullish Signals
Cooper Companies reported adjusted earnings of $1.15 per share for the third quarter, which beat Wall Street estimates despite missing on top-line revenue.
Retaining the CooperSurgical business unit may provide a buffer to earnings in the short term compared to a potential sale.
Risk Factors
The company's fourth-quarter revenue forecast of $1.05 to $1.09 per share came in well below Wall Street's consensus estimate of $1.19.
U.S. distributor destocking for the CooperVision contact-lens business will continue to hurt fourth-quarter numbers through the end of fiscal 2026.
The decision to not sell CooperSurgical removed a potential deal catalyst that had previously driven up the stock price, leading to investor disappointment.
Shares of The Cooper Companies, Inc. (COO) dropped 6.0% to $63.62 on Wednesday, September 9, 2026, as trading volume surged to 3.9 million shares. This significant decline occurred within the context of broader market uncertainty and questions regarding the S&P 500's opening trajectory, rather than being driven by specific negative news related to the company's medical instruments and supplies business.
The stock's performance highlights a disconnect between the price action and fundamental company developments, as there were no reported earnings misses, analyst downgrades, or product-specific issues. With a market capitalization of $12.4 billion, Cooper Companies remains a major player in the healthcare sector, making this volatility notable for investors tracking medical device manufacturers despite the lack of intrinsic corporate catalysts.
Analysts and shareholders are now monitoring whether this selloff represents a temporary technical correction or the beginning of a sustained downturn linked to macro sentiment. The absence of company-specific negative drivers suggests the move is primarily driven by index-related trading flows, but continued weakness could signal deeper concerns regarding healthcare valuations or sector-wide pressure.
📉 COO shares fell 6.0% to $63.62 due to market uncertainty.
📊 Trading volume hit 3.9 million as investors exited positions.
💰 Company retains $12.4 billion market cap with no earnings misses.
⚠️ Selling pressure risks sustained correction if macro weakness persists.
📉 COO shares plunged 6.0% to $63.62 on September 9, 2026, driven by broader market uncertainty rather than company-specific news.
📊 Trading volume spiked to 3.9 million shares as investors exited positions amid questions about the S&P 500's direction.
💰 The company maintains a $12.4 billion market capitalization while facing no reported earnings misses or analyst downgrades.
🔍 Investors are evaluating whether this decline is a buying opportunity or indicative of deeper healthcare sector concerns.
⚠️ Continued selling pressure could signal sustained correction risks if macro weakness persists without fundamental stabilization.
Risk Factors
Shares dropped 6.0% on Sept 9, 2026 amid market jitters.
Volume surged to 3.9M shares as investors exited.
Risk Factors
Shares dropped 6.0% to $63.62 on September 9, 2026, reflecting heightened investor caution and selling pressure linked to broader market jitters.
Trading volume surged to 3.9 million shares as investors exited positions, indicating a lack of immediate support at current price levels.
The Cooper Companies, Inc. (NASDAQ: COO) is scheduled to report its third-quarter fiscal 2026 earnings results after the market close on September 9th. Wall Street analysts have set a consensus EPS estimate of $1.11 and revenue expectations at $1.1 billion. The anticipated earnings growth is modest, representing only a 0.9% increase over the year-ago result of $1.10 per share, while revenue is expected to rise by 3.6% compared to the prior period.
Analysts are closely monitoring whether Cooper can maintain its historically strong profitability metrics, specifically the 64.7% gross margin and 16.4% operating margin recorded in the previous quarter. The company's recent track record of beating consensus estimates suggests consistent execution, but investors will scrutinize if this performance can be sustained amidst potential revenue headwinds or volume pressures.
Key areas of focus for shareholders include segment-level performance across its diverse medical device categories and geographic mix, particularly how international markets compare to domestic operations. Management commentary regarding the product pipeline, regulatory approvals, and customer adoption trends will be critical in determining if the anticipated revenue softness is a temporary pause or signals a broader deceleration.
The stock is currently trading at $70.64 as it approaches the earnings release, positioning investors to evaluate if actual results align with the modest growth expectations embedded in consensus estimates. The report will provide clarity on pricing discipline, operational efficiency, and future guidance for fiscal year 2026, which are essential for calibrating forward expectations regarding the company's core markets.
📅 Cooper Companies reports Q3 fiscal 2026 earnings after market close on September 9th.
💰 Analysts expect consensus EPS of $1.11 and revenue of $1.1 billion.
📈 Expected EPS shows a modest 0.9% year-over-year increase from the prior period.
📊 Revenue is projected to grow by 3.6% compared to Q3 fiscal 2025.
🛡️ Investors will watch for margin sustainability and international market performance.
📅 Cooper Companies is scheduled to report Q3 fiscal 2026 earnings after market close on September 9th.
💰 Analysts expect consensus EPS of $1.11 and revenue of $1.1 billion for the upcoming quarter.
📈 The expected EPS represents a modest 0.9% year-over-year increase from the prior period's $1.10 result.
📊 Revenue is projected to grow by 3.6% compared to the $1.07 billion reported in Q3 fiscal 2025.
🛡️ The company previously achieved a robust 64.7% gross margin and 16.4% operating margin in the prior quarter.
🔍 Investors will watch for margin sustainability to gauge pricing power and manufacturing efficiency.
🌍 Segment-level performance and geographic mix, especially international markets, are critical drivers.
🚀 Management commentary on the product pipeline and regulatory approvals will frame future expectations.
💼 The stock trades at $70.64 ahead of the earnings release to be tested against fundamental trajectory.
📉 Recent execution shows a beat in the last quarter, though statistical significance for forecasting is limited.
Cooper Standard (NYSE: CPS) has received validation from the Science Based Targets initiative (SBTi) for its near-term science-based greenhouse gas emissions reduction targets. This confirmation indicates that the company's goals align with current climate science and SBTi criteria, reinforcing its commitment to environmental stewardship.
The validated plan targets a 60.83% cut in absolute Scope 1 and 2 emissions and a 31.73% reduction in selected Scope 3 emissions by 2035, using 2024 as the base year. To achieve these objectives, Cooper Standard plans to focus on operational decarbonization, energy efficiency, process improvements, expanded renewable energy use, supplier collaboration, and innovation for lower-carbon products.
This milestone supports the company's broader sustainability strategy, including goals of carbon neutrality by 2040 in Europe and 2050 globally. CEO Jeffrey Edwards stated that the validation reflects a focus on measurable targets backed by a clear roadmap, strengthening the business and delivering value to customers and shareholders through responsible long-term growth.
⚠️ Note: The provided text discusses Cooper Standard (CPS), not the target ticker COO. Per isolation rules, no points can be generated for COO as there is no substantive information about it in the source text.
SKIP.
🌱 Cooper Standard (CPS) received SBTi validation for its near-term science-based greenhouse gas emissions reduction targets.
📉 The company commits to reducing absolute Scope 1 and Scope 2 emissions by 60.83% by 2035 from a 2024 base year.
🌍 Cooper Standard also targets a 31.73% reduction in selected Scope 3 emissions, including purchased goods and upstream transportation, by 2035.
⚡ To meet these goals, the company will focus on energy efficiency, process improvements, and expanded renewable energy adoption.
🤝 Cooper Standard plans to collaborate with suppliers to address value chain emissions and invest in lower-carbon manufacturing innovation.
🎯 These validated targets support the company's long-term aspiration of achieving carbon neutrality by 2040 in Europe and 2050 globally.
📈 Shares gained 1.94% on September 2, reflecting a positive market reaction to the sustainability milestone.
Cooper Standard received SBTi validation for its near-term emissions targets, confirming alignment with climate science and strengthening its business case for sustainable growth.
The company's commitment to a 60.83% reduction in Scope 1 and 2 emissions by 2035 demonstrates significant progress toward its carbon neutrality goals.
Harris Oakmark recently released its second-quarter 2026 investor letter for the Oakmark Global Fund, a non-diversified fund focusing on long-term capital appreciation. The fund delivered a 7.89% return in Q2, lagging the MSCI World Index's 13.76% gain, with energy and industrials driving performance while health care and consumer discretionary detracted. The firm emphasizes evaluating companies based on competitive advantages, cash flow potential, and valuation rather than market predictions.
The Oakmark Global Fund highlighted The Cooper Companies (NASDAQ: COO) as a newly added position in its Q2 2026 update. The medical device company, which operates through CooperVision and CooperSurgical segments, closed at $68.51 per share on July 14, 2026. Oakmark views the stock as an attractive entry point following a sharp pullback alongside the broader medical technology sector, noting it trades at a meaningful discount to public peers, private market transactions, and its own trading history.
The fund praises Cooper's oligopolistic market structure in contact lenses, which offers significant barriers to entry, recurring revenue streams, and consistent positive pricing dynamics supporting mid-single-digit growth. Oakmark is encouraged by the company's track record of gaining market share through specialty lenses and a unique private-label strategy. Additionally, recent steps to improve free cash flow conversion, reaccelerate growth, and optimize the product portfolio have strengthened the investment thesis.
Despite being added by Oakmark, The Cooper Companies is not currently on Insider Monkey's list of 40 most popular stocks among hedge funds heading into 2026. Hedge fund holdings decreased slightly from 53 portfolios in Q1 to 49 at the end of Q1 2026. While acknowledging the risk and potential, the article suggests that some AI stocks may offer higher returns over a shorter timeframe compared to Cooper, though it maintains that Cooper represents a solid value play for investors seeking exposure to medical devices.
📈 Harris Oakmark added Cooper Companies (COO) as a new Q2 2026 position.
💰 Stock closed at $68.51 with a 7.35% one-month return and 3.95% annual loss.
🏢 Business spans contact lenses via CooperVision and women's health via CooperSurgical.
💎 Fund cites oligopolistic barriers to entry and recurring revenue in the lens market.
🚀 Company focuses on improving cash flow, growth reacceleration, and portfolio optimization.
📈 Harris Oakmark's Oakmark Global Fund added The Cooper Companies (COO) as a new position in its Q2 2026 investor letter.
💰 The stock closed at $68.51 per share on July 14, 2026, representing a 7.35% one-month return but a 3.95% loss over the past 52 weeks.
🏢 Cooper operates through two main segments: CooperVision, which manufactures contact lenses, and CooperSurgical, focused on women's health products.
📉 The company has a market capitalization of $13.36 billion and trades at a meaningful discount to public peers and private market transactions.
💎 Oakmark highlights the oligopolistic structure of the contact lens industry as providing significant barriers to entry and recurring revenue streams.
🚀 Recent strategic steps include improving free cash flow conversion, reaccelerating growth, and optimizing the product portfolio.
📊 Cooper has an impressive track record of gaining market share, attributed to its leading position in specialty lenses and unique private-label strategy.
📉 Hedge fund interest is waning slightly, with 49 portfolios holding the stock at the end of Q1 2026 compared to 53 in the previous quarter.
🤖 The article notes that while Cooper is a value play, some AI stocks may offer higher returns over a shorter timeframe according to the fund's perspective.
📰 Needham recently raised its price target on COO to $101, indicating external analyst confidence in the company's prospects.
Bullish Signals
New institutional position signals long-term value confidence.
Trades at meaningful discount to peers and history.
Oligopolistic structure with high barriers and pricing power.
Gaining market share via specialty lenses and private label.
Management improving cash flow, growth, and portfolio.
Needham raised price target to $101.
Risk Factors
Underperformed benchmark with 7.89% return vs 13.76% index gain in Q2 2026.
Hedge fund holdings dropped from 53 to 49 portfolios in Q1 2026.
AI stocks may offer higher short-term returns than The Cooper Companies.
Bullish Signals
The Oakmark Global Fund initiated a new position in The Cooper Companies, signaling institutional confidence in its long-term value.
The stock trades at a meaningful discount relative to public peers, private market transactions, and its own historical trading levels.
CooperVision benefits from an oligopolistic market structure with high barriers to entry and historically consistent positive pricing dynamics.
The company has demonstrated an impressive track record of gaining contact lens market share through specialty lenses and a unique private-label strategy.
Management has taken recent steps to improve free cash flow conversion, reaccelerate growth, and optimize the product portfolio.
Needham raised its price target on COO to $101, reflecting positive analyst sentiment regarding the company's fundamentals.
Risk Factors
The Oakmark Global Fund underperformed its benchmark in Q2 2026, delivering a 7.89% return compared to the MSCI World Index's 13.76% gain.
Hedge fund portfolios holding The Cooper Companies decreased from 53 in Q1 2026 to 49 at the end of Q1 2026, indicating some institutional rotation away from the stock.
The article suggests that some AI stocks may hold greater promise for delivering higher returns over a shorter timeframe compared to The Cooper Companies.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)